Is Akero Therapeutics ( AKRO ) Stock Outpacing Its Medical Peers This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Humana (HUM) have performed compared to their sector so far this year.
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector ...
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO - Akero Therapeutics ( NASDAQ:AKRO )
NEW ORLEANS, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ( "KSF" ) , announces that KSF has commenced an investigation into Akero Therapeutics, Inc. AKRO.
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
Is Boston Scientific ( BSX ) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
Has Akero Therapeutics ( AKRO ) Outpaced Other Medical Stocks This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Stryker (SYK) have performed compared to their sector so far this year.
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will ...
Does Akero Therapeutics ( AKRO ) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.1% in Akero Therapeutics (AKRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results support potential of efruxifermin ( EFX ) to reduce risk of fibrosis progression in patients with pre-cirrhotic ( F2-F3 ) MASH Results support potential of efruxifermin ( EFX ) to reduce risk of fibrosis progression in patients with pre-cirrhotic ( F2-F3 ) MASH ...
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Are Medical Stocks Lagging Akero Therapeutics ( AKRO ) This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Akero ( AKRO ) Q2 Loss Narrows 6%
Akero Therapeutics ( NASDAQ:AKRO ) , a biotechnology company focused on developing medicines for fatty liver diseases, released its second-quarter results on August 8, 2025. The most notable news in this quarter was continued progress in clinical trials for its lead drug candidate, efruxifermin ( ...
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine ...
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Akero Therapeutics ( NASDAQ:AKRO ) , Apartment Inv & Mgmt ( NYSE:AIV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Ritu Baral initiated coverage on Akero Therapeutics, Inc.
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., June 03, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc.
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will ...
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., May 28, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. AKRO, a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the ...
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response ...
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY ...
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Results support potential benefit of efruxifermin ( EFX ) to elicit fibrosis improvement in patients with compensated cirrhosis ( F4 fibrosis ) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress ...
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY ...
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., May 09, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc.
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Long-Term Shareholders Have Rights - If You Hold Akero Therapeutics, Inc. ( NASDAQ: AKRO ) ; Integra Lifesciences Holdings Corporation ( NASDAQ: IART ) ; Mercury Systems, Inc. ( NASDAQ: MRCY ) ; or Virtu Financial Inc. ( NASDAQ: VIRT ) , Contact Grabar Law Office - Integra Lifesciences ( NASDAQ:IART ) , Akero Therapeutics ( NASDAQ:AKRO )
PHILADELPHIA, May 05, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. AKRO: Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you have held Akero Therapeutics, Inc.
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., April 30, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc.
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Akero Therapeutics ( NASDAQ:AKRO )
NEW YORK, April 23, 2025 ( GLOBE NEWSWIRE ) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Shareholders should email [email protected]; please contact only if shares acquired before September 13, 2022
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Akero Therapeutics ( NASDAQ:AKRO )
NEW YORK, April 07, 2025 ( GLOBE NEWSWIRE ) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Shareholders should email [email protected]; please contact only if shares acquired before September 13, 2022
